Jul 24, 2018 7:00 am EDT Acasti Pharma Awarded Composition-of-Matter Patent by the U.S. Patent and Trademark Office
Jul 2, 2018 5:00 pm EDT Acasti Pharma Announces Annual Performance Grants of Stock Options, Amendment of Stock Option Plan and Issuance of Common Shares in Payment of Outstanding Interest under Debentures
Jun 11, 2018 8:07 pm EDT Acasti Pharma Reports on Positive Feedback Following Today’s Presentation at the XVIII International Symposium on Atherosclerosis
Jun 6, 2018 7:00 am EDT Acasti Pharma to Present at the XVIII(th) International Symposium on Atherosclerosis
May 18, 2018 7:00 am EDT Acasti Pharma Retains Crescendo Communications for Investor Relations Services in the United States
Apr 27, 2018 8:00 am EDT Acasti Pharma Appoints Donald Olds to its Board of Directors and Audit Committee
Apr 2, 2018 8:00 am EDT Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures
Mar 14, 2018 8:00 am EDT Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia